Technology Other News 01 Feb 2020 Navia life Care join ...

Navia life Care join hands with Aptar Pharma to launch MyAdhero app

DECCAN CHRONICLE
Published Feb 1, 2020, 9:05 am IST
Updated Feb 1, 2020, 9:05 am IST
Aptar Pharma along with Lupin Limited has launched ADHERO which helps patients with chronic respiratory diseases.
With the help of this initiative, Navia Life Care is helping Aptar Pharma to offer India’s first e-connected inhaler for Lupin Pharmaceuticals.
 With the help of this initiative, Navia Life Care is helping Aptar Pharma to offer India’s first e-connected inhaler for Lupin Pharmaceuticals.

Navia Life Care has recently joined hands with Aptar Pharma to launch the digital ecosystem of MyAdhero App. ADHERO is India’s first connected device for metered-dose inhalers (MDI) whereas MyAdhero App which is its technology platform, including a Patient App, Care Provider App and the Doctor Portal.

Aptar Pharma along with Lupin Limited has launched ADHERO which helps patients with chronic respiratory diseases. It tracks their MDI usage and facilitate improved adherence to their prescribed therapy.

 

With the help of this initiative, Navia Life Care is helping Aptar Pharma to offer India’s first e-connected inhaler for Lupin Pharmaceuticals. The inhaler is connected to their technology platform through a patient-facing mobile app, a dashboard for doctors and an advanced analytics tool that will provide Aptar and Lupin greater understanding and insights into patient behavior. Also, it is benefitting patients through improved adherence and compliance.

By connecting ADHERO device to their MyAdhero App, patients can access the information on their smartphones. The app sends reminders, provide contextual health alerts based on factors like the Air Quality Index at the patient’s current location and enable visual analytics. Patients can also grant their physician access to their information and medical tracking data through the dashboard portal as well as the app.

 

Click on Deccan Chronicle Technology and Science for the latest news and reviews. Follow us on Facebook, Twitter

...




ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT